Mumbai, Nov 13 (UNI) Shreya Life Sciences, India, today announced the launch of world's first recombinant DNA human insulin buccal spray under the brand name of Oral-Recosulin.
Ultra Rapid Prandial Glucose Regulator is a buccal insulin spray for the treatment of Type I and Type II diabetes that is based on the technology developed by the company's US collaborator Generex Biotechnology.
It is observed that needle phobia is a primary reason, which at times prevents the patient from taking insulin therapy, although required. Oral-Recosulin is an alternative available for those diabetics who have an acute injection phobia. ''We feel that Oral-Recosulin is a simple solution for a worldwide problem, as diabetics would prefer buccal delivery of the drug to injections, because it offers superior pharmacodynamic profile besides being pain free, Mr Ram Shelat, Director, Domestic Business, Shreya Life Sciences, said in a release here today.
''While the IDF addresses issues related to diabetes and its global impact all year round, November 14 has been chosen as its commemorative day. From last two years their aim has been to raise awareness about the seriousness of childhood diabetes,'' Mr Shelat said in the release.
UNI AR SR SKB1638